Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination information

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document (PDF 544 KB)

Crohn's disease (moderate to severe) - vedolizumab: committee papers information

Crohn's disease (moderate to severe) - vedolizumab: appraisal consultation

Crohn's disease (moderate to severe) - vedolizumab: appraisal consultation document

Crohn's disease (moderate to severe) - vedolizumab: appraisal consultation document (PDF 708 KB)

Crohn's disease (moderate to severe) - vedolizumab: committee papers information

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1 (PDF 10.23 MB)

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 2

Crohn's disease (moderate to severe) - vedolizumab: final scope

Crohn's disease (moderate to severe) - vedolizumab: final matrix

Crohn's disease (moderate to severe) - vedolizumab: NICE response to comments on the draft matrix and scope

Crohn's disease (moderate to severe) - vedolizumab: equality impact assessment

Crohn's disease (moderate to severe) - vedolizumab: draft scope for re-scope consultation (post referral)

Crohn's disease (moderate to severe) - vedolizumab: draft matrix for re-scope consultation (post referral)

Crohn's disease (moderate to severe) - vedolizumab: draft scope for consultation (pre-referral) - October 2013 

Crohn's disease (moderate to severe) - vedolizumab: provisional matrix (pre-referral) - October 2013